DGIdb - DOLASETRON Drug Record

DOLASETRON chembl:CHEMBL2368925 Approved

Alternate Names:

DOLASETRON
ANZEMET CINV
DOLASETRONUM
DOLASÉTRON
pubchem.compound:60654
chembl:CHEMBL2368925
chemidplus:115956-12-2
drugbank:00757
rxcui:68091

Drug Info:

Year of Approval	1997
Drug Class	antiemetics
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiemetic

(2 More Sources)

Publications:

Conroy et al., 1994, Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group., Am. J. Clin. Oncol.
Reith et al., 1995, Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist., Drug Metab. Dispos.
Eisenberg et al., 2003, Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron., Cancer
Boeijinga et al., 1992, Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells., Eur. J. Pharmacol.
Gregory et al., 1998, 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy., Drugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Gan, 2005, Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?, CNS Drugs
Monaca-Charley et al., 2003, Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis., J. Neurol.
Hui et al., Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist., Cancer Pract
Balfour et al., 1997, Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery., Drugs
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Kuryshev et al., 2000, Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels., J. Pharmacol. Exp. Ther.
Quraishi SA et al., 2011, 5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities., J Clin Anesth

DOLASETRON NOS1AP

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21663814

Sources:
PharmGKB
DOLASETRON HTR3A

Interaction Score: 2.28

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name dolasetron mesylate, Anzemet

Novel drug target Established target

PMIDs:
8141114 7493546 14635083 1397053 9506240 11752352 15740177 14586600 9341357 9257083

Sources:
TdgClinicalTrial TEND TTD
DOLASETRON HTR3C

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
DOLASETRON HTR3D

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name dolasetron mesylate,Anzemet

PMIDs:
None found

Sources:
TdgClinicalTrial
DOLASETRON HTR3E

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
DOLASETRON KCNQ1

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11046096

Sources:
NCI
DOLASETRON HTR3B

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
DOLASETRON CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528

Sources:
PharmGKB

TEND: DOLASETRON
- Version: 01-August-2011
Alternate Names:

DOLASETRON Primary Drug Name

Drug Info:

Drug Class antiemetics

Year of Approval 1997

Publications:
TdgClinicalTrial: DOLASETRON
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiemetic

Drug Class Small Molecule

FDA Approval approved

Publications:
NCI: DOLASETRON
- Version: 14-September-2017
Alternate Names:

C1153 NCI drug code

Drug Info:

Publications:

Kuryshev et al., 2000, Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels., J. Pharmacol. Exp. Ther.

PharmGKB: dolasetron

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Quraishi SA et al., 2011, 5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities., J Clin Anesth

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

TTD: Dolasetron
- Version: 2020.06.01
Alternate Names:

D00YLW TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2368925
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	dolasetron mesylate, Anzemet
Novel drug target	Established target

Trial Name	dolasetron mesylate,Anzemet
Novel drug target	Established target

DOLASETRON Drug Record

DOLASETRON chembl:CHEMBL2368925 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21663814

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name dolasetron mesylate, Anzemet Novel drug target Established target

PMIDs: 8141114 7493546 14635083 1397053 9506240 11752352 15740177 14586600 9341357 9257083

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name dolasetron mesylate,Anzemet Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name dolasetron mesylate,Anzemet

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name dolasetron mesylate,Anzemet Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11046096

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name dolasetron mesylate,Anzemet Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9187528

Sources: PharmGKB

TEND: DOLASETRON

Alternate Names: DOLASETRON Primary Drug Name

Drug Info: Drug Class antiemetics Year of Approval 1997

Publications:

TdgClinicalTrial: DOLASETRON

Alternate Names:

Drug Info: Drug Indications antiemetic Drug Class Small Molecule FDA Approval approved

Publications:

NCI: DOLASETRON

Alternate Names: C1153 NCI drug code

Drug Info:

Publications: Kuryshev et al., 2000, Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels., J. Pharmacol. Exp. Ther.

PharmGKB: dolasetron

Alternate Names:

Drug Info:

TTD: Dolasetron

Alternate Names: D00YLW TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2368925

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
21663814

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name dolasetron mesylate, Anzemet

Novel drug target Established target

PMIDs:
8141114 7493546 14635083 1397053 9506240 11752352 15740177 14586600 9341357 9257083

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name dolasetron mesylate,Anzemet

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
11046096

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name dolasetron mesylate,Anzemet

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
9187528

Sources:
PharmGKB

Alternate Names:

DOLASETRON Primary Drug Name

Drug Info:

Drug Class antiemetics

Year of Approval 1997

Drug Info:

Drug Indications antiemetic

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1153 NCI drug code

Publications:

Kuryshev et al., 2000, Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels., J. Pharmacol. Exp. Ther.

Alternate Names:

D00YLW TTD Drug ID